HLA-E expression and its clinical relevance in human renal cell carcinoma

The non-classical human leukocyte antigen E (HLA-E) expression is frequently overexpressed in tumor diseases, transplants and virus-infected cells and represents an immunomodulatory molecule by binding to the receptors CD94/NKG2A, -B and –C on NK and T cells. Due to its immune suppressive features HLA-E expression might represent an important mechanism of tumors to escape immune surveillance. While an aberrant expression of the non-classical HLA-G antigen in human renal cell carcinoma (RCC) has been demonstrated to be associated with a worse outcome of patients and reduced sensitivity to immune effector cell-mediated cytotoxicity, the expression and function of HLA-E has not yet been analyzed in this tumor entity. Higher levels of HLA-E transcripts were detected in all RCC cell lines and tumor lesions, which were tested in comparison to normal kidney epithelium. Immunohistochemical staining of a tissue microarray (TMA) using the HLA-E-specific monoclonal antibody TFL-033 recognizing the cytoplasmic HLA-E α-chain as monomer revealed a heterogeneous HLA-E expression in RCC lesions with the highest frequency in chromophobe RCC when compared to other RCC subtypes. HLA-E expression did not correlate with the frequency of CD3+, CD4+, CD8+ and FoxP3+ immune cell infiltrations, but showed an inverse correlation with infiltrating CD56+ cells. In contrast to HLA-G, HLA-E expression in RCCs was not statistically significant associated with a decreased disease specific survival. These data suggest that HLA-E overexpression frequently occurs in RCC and correlates with reduced immunogenicity.

[1]  S. H. van der Burg,et al.  The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma , 2015, Oncotarget.

[2]  T. Whiteside.  Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV , 2015, Cancer Microenvironment.

[3]  R. Blasczyk,et al.  The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch , 2015, Immunogenetics.

[4]  P. Terasaki,et al.  Immunobiology of HLA Class-Ib Molecules in Transplantation , 2015 .

[5]  M. Donia,et al.  Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma , 2015, Human vaccines & immunotherapeutics.

[6]  Camilla Sampaoli,et al.  Monoclonal antibodies to HLA‐E bind epitopes carried by unfolded β2m‐free heavy chains , 2015, European journal of immunology.

[7]  B. Seliger,et al.  Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis , 2015, Oncoimmunology.

[8]  P. Terasaki,et al.  The Monospecificity of Novel Anti-HLA-E Monoclonal Antibodies Enables Reliable Immunodiagnosis, Immunomodulation of HLA-E, and Upregulation of CD8+ T Lymphocytes. , 2015, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[9]  M. Sznol,et al.  Therapeutic combinations of immune-modulating antibodies in melanoma and beyond. , 2015, Seminars in oncology.

[10]  M. Tilanus,et al.  Peptide-induced HLA-E expression in human PBMCs is dependent on peptide sequence and the HLA-E genotype. , 2015, Tissue antigens.

[11]  E. Tartour,et al.  Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma , 2015, Oncoimmunology.

[12]  B. Seliger,et al.  Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma , 2015, Oncoimmunology.

[13]  B. Seliger,et al.  Immune signature of tumor infiltrating immune cells in renal cancer , 2015, Oncoimmunology.

[14]  Q. Tao,et al.  Interferon regulatory factor 8 functions as a tumor suppressor in renal cell carcinoma and its promoter methylation is associated with patient poor prognosis. , 2014, Cancer letters.

[15]  B. Seliger,et al.  Identification of 14-3-3β Gene as a Novel miR-152 Target Using a Proteome-based Approach* , 2014, The Journal of Biological Chemistry.

[16]  H. Putter,et al.  Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study , 2014, BMC Cancer.

[17]  B. Seliger,et al.  Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation , 2014, Journal of Translational Medicine.

[18]  P. Terasaki,et al.  Gastric cancer progression may involve a shift in HLA‐E profile from an intact heterodimer to β2‐microglobulin‐free monomer , 2014, International journal of cancer.

[19]  P. Kuppen,et al.  Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients , 2013, British Journal of Cancer.

[20]  F. Dallocchio,et al.  Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding , 2013, Molecular and Cellular Biochemistry.

[21]  You-jian He,et al.  Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer , 2013, Medical Oncology.

[22]  Pieter Wesseling,et al.  The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells , 2013, Immunology.

[23]  Longmei Zhao,et al.  Full-length HLA-G1 and truncated HLA-G3 differentially increase HLA-E surface localization. , 2012, Human immunology.

[24]  B. Seliger,et al.  The role of classical and non-classical HLA class I antigens in human tumors. , 2012, Seminars in cancer biology.

[25]  Hong Jiang,et al.  Human leukocyte antigen E in human cytomegalovirus infection: friend or foe? , 2012, Acta biochimica et biophysica Sinica.

[26]  A. Poprach,et al.  HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma , 2012, Diagnostic Pathology.

[27]  E. Carosella,et al.  The tolerogenic interplay(s) among HLA-G, myeloid APCs, and regulatory cells. , 2011, Blood.

[28]  E. Donadi,et al.  Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness. , 2011, Histology and histopathology.

[29]  P. Natali,et al.  Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. , 2011, Neoplasia.

[30]  B. Seliger,et al.  Monitoring peri-operative immune suppression in renal cancer patients. , 2011, Oncology reports.

[31]  Federica Cavallo,et al.  2011: the immune hallmarks of cancer , 2011, Cancer Immunology, Immunotherapy.

[32]  F. Marincola,et al.  Association of IFN-γ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines , 2011, Clinical Cancer Research.

[33]  H. Putter,et al.  HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients , 2010, The Journal of Immunology.

[34]  J. Casanova,et al.  A novel form of cell type-specific partial IFN-gammaR1 deficiency caused by a germ line mutation of the IFNGR1 initiation codon. , 2010, Human molecular genetics.

[35]  X. Zhang,et al.  Characterization of HLA-G expression in renal cell carcinoma. , 2009, Tissue antigens.

[36]  P. Debré,et al.  HLA-E upregulation on IFN-γ-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT , 2009, Bone Marrow Transplantation.

[37]  B. Seliger,et al.  Expression and regulation of non-classical HLA-G in renal cell carcinoma. , 2008, Tissue antigens.

[38]  S. Hirohashi,et al.  Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.

[39]  A. Moreau,et al.  Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells1 , 2006, The Journal of Immunology.

[40]  B. Seliger,et al.  Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? , 2004, The Journal of urology.

[41]  B. Seliger,et al.  Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. , 2003, Cancer research.

[42]  W. Ferlin,et al.  Expression of CD94-NKG2A inhibitory receptor is restricted to a subset of CD8+ T cells. , 2003, Trends in immunology.

[43]  Hein Putter,et al.  Down-Regulation of HLA-A Expression Correlates with a Better Prognosis in Colorectal Cancer Patients , 2002, Laboratory Investigation.

[44]  K. Wright,et al.  Loss of Interferon-γ Inducibility of TAP1 and LMP2 in a Renal Cell Carcinoma Cell Line , 2000 .

[45]  D. Speiser,et al.  CD28‐negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients , 1999, European journal of immunology.

[46]  F. Garrido,et al.  Expression of HLA G in human tumors is not a frequent event , 1999, International journal of cancer.

[47]  B. Seliger,et al.  Induction of immunogenicity of a human renal‐cell carcinoma cell line by TAP1‐gene transfer , 1999, International journal of cancer.

[48]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[49]  D. Goodlett,et al.  HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. , 1998, Journal of immunology.

[50]  J. Coligan,et al.  Recognition of Human Histocompatibility Leukocyte Antigen (HLA)-E Complexed with HLA Class I Signal Sequence–derived Peptides by CD94/NKG2 Confers Protection from Natural Killer Cell–mediated Lysis , 1998, The Journal of experimental medicine.

[51]  J. Bell,et al.  HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C , 1998, Nature.

[52]  B. Seliger,et al.  Analysis of the MHC Class I Antigen Presentation Machinery in Human Embryonal Carcinomas: Evidence for Deficiencies in TAP, LMP and MHC Class I Expression and their Upregulation by IFN‐γ , 1997, Scandinavian journal of immunology.

[53]  Fan Yang,et al.  Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients. , 2015, Cellular immunology.

[54]  I. Ellis,et al.  Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis , 2006, International journal of cancer.

[55]  G. Ferrara,et al.  HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. , 2005, Human immunology.